Oral contraceptives and venous thrombosis. An ... - Ãjvind Lidegaard

More documents

Recommendations

Info

DefinitionsExpert Meeting on theBenefits and Risks of Oral ContraceptivesSaturday, 12 December 2009, 11am to 4 pmMaritim Pro Arte Hotel, Friedrichstrasse 151, BerlinFaculty:Prof. Corinne de Vries Dept Pharmacy & Pharmacology, Bath Univ, UKDr. Jürgen DingerDr. Diana Mansour Gynaecologist, Contraception and sexual health Newcastle,Prof. Samuel ShapiroDr. Anne Szarewski Clinical Officer family planning, Margaret Pyke, UKDr. Carolyn L. Westhoff Director, division of Family Planning and PreventivInvitation sent out by Bayer in November 2009
Preliminary AgendaDefinitions• Welcome/Objectives• The role of pharmacoepidemiology in assessing the benefit-risk profile of oralcontraceptivesThe epidemiological evidence on oral contraceptives containing drospirenonePost-authorization safety studies• EURAS - design, results and critique• Ingenix - design, results and critique• LASS study - design, results and critique• Discussion, Question & Answers• Current guidelines and initiatives on Good Pharmacoepidemiological PracticeThe epidemiological evidence on oral contraceptives containing drospirenone (part II)• MEGA study - design, results and critique• Danish Cohort study - design, results and critique• Dienogest Case Control study - design, results and critique• PEM study - design, results and critique• Discussion, Questions & AnswersResponsible Prescribing of oral contraceptivesGeneral Panel discussion, Question &Answers sessionSummary
Page 1 and 2: Oral contraceptionand venous thromb
Page 3 and 4: COC DK 2009: Progestogen typesCypro
Page 6: OC and VTE: Progestagen typeadjuste
Page 9 and 10: VTE and drospirenoneVTE Risk Rate r
Page 11: Research story• 1960s: OC were in
Page 16 and 17: Critique In the Danish study the co
Page 18 and 19: EditorialGrimes, Obstet Gynecol Nov
Page 20 and 21: Research using vital Definitionsrec
Page 22 and 23: Research story• 2010, Jan: Shapir
Page 24 and 25: Research story• 2010, Jan: Shapir
Page 27 and 28: Oral contraception and VTEA Nationa
Page 29 and 30: InclusionMaterial• All women in D
Page 31 and 32: MaterialExclusions (
Page 33 and 34: Risk of VTE according to yearAdjust
Page 35 and 36: Relative risk versus non-useRate ra
Page 41 and 42: VTE and drospirenoneVTE IR Rate rat
Page 43 and 44: HC and VTE according to oestrogendo
Page 45 and 46: VTE and drospirenoneVTE IR Rate rat
Page 47 and 48: Blomenkamp88-92WHO1989-93Jick1991-9
Page 49 and 50: OCs and SHBG changes400% increase i
Page 51 and 52: COC and VTE: Conclusion• COC incr
Page 53 and 54: CT, AMI and VTE in DK 2001-2009Preg
Page 55 and 56: COC and VTE: Perspectives• Parent
Page 57 and 58: COC and VTE: Perspectives• Parent
Page 59: COC and VTE: PerspectivesThankswww.

Oral contraceptives and venous thrombosis. An ... - Ãjvind Lidegaard

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?

Oral contraceptives and venous thrombosis. An ... - Ãjvind Lidegaard